Oruka Therapeutics, Inc. (ORKA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$97.62

From 52W high−16.02%

Volume1.91M

Market cap$6.29B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$97.62

From 52W high

−16.02%

Volume

1.91M

Market cap

$6.29B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−38.3x

P/E (TTM)

—

RSI (14)

49.3

MomentumView details →

1D Return

−2.83%

YTD Return

+213.88%

SummaryUpdated Jun 1, 2026

Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a clinical-stage biotechnology company founded to develop innovative monoclonal antibody treatments for inflammatory and immunological diseases. Based in Menlo Park, California, the company focuses specifically on developing therapies for psoriasis and other immune-mediated inflammatory conditions. As a pre-revenue biotech firm, Oruka is currently advancing its pipeline of experimental drugs through clinical trials, with its lead candidates being ORKA-001 and ORKA-002.

Ask drillr about Oruka Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−38.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

5.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−11.92%

ROA (TTM)

−11.66%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+45.47%

FCF YoY

−3.30%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+53.71%

EBITDA YoY

−27.51%

MomentumView details →

1D Return

−2.83%

YTD Return

+213.88%

1Y Return

+511.82%

RSI (14)

49.3

vs 50D SMA

−1.31%

vs 200D SMA

+55.49%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

38.51x

Quick Ratio

38.51x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.55

EPS Surprise

−7.32%

Beats (12Q)

3/12

Next Q EPS Est

−$0.60

Avg Surprise (4Q)

7.86%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−132.89M

Op. CF (TTM)

−100.92M

Next earningsNov 11, 2026 →

Latest newsMore news →

Oruka Therapeutics, Inc. appointed Todd Edwards as Chief Commercial Officer, effective with a base salary of $525,000, a target bonus of 40% of annual base salary, a signing bonus of $200,000, and equity grants including a stock option for 20,000 shares and restricted stock units for 100,000 shares of Oruka common stock.28d ago

Similar companies

Centessa Pharmaceuticals plcCNTA Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H02335.HK Tennor Therap-b06872.HK Terns Pharmaceuticals, Inc.TERN 科前生物688526.SH Kiniksa Pharmaceuticals, Ltd.KNSA Find similar companies →

Latest newsMore news →

BlackRock Inc. acquired a new minority stake in Oruka Therapeutics, Inc., purchasing 4,990,181 shares valued at approximately $474,916,000, representing about 8.27% ownership, as disclosed in a 13F filing.26d ago Oruka Therapeutics, Inc. appointed Todd Edwards as Chief Commercial Officer, effective with a base salary of $525,000, a target bonus of 40% of annual base salary, a signing bonus of $200,000, and equity grants including a stock option for 20,000 shares and restricted stock units for 100,000 shares of Oruka common stock.28d ago